NYSE:QGEN - Qiagen Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$35.90 +0.05 (+0.14 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$35.47
Today's Range$35.47 - $35.91
52-Week Range$30.20 - $36.34
Volume54,772 shs
Average Volume818,253 shs
Market Capitalization$8.16 billion
P/E Ratio28.23
Dividend YieldN/A
Beta1.03

About Qiagen (NYSE:QGEN)

Qiagen logoQIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions. It also provides Ingenuity Variant Analysis, a cloud-based platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence-based decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web-based portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products. In addition, the company offers instrumentation systems for laboratories. Its automation platforms include QIAsymphony, a modular system; GeneReader NGS System, a sample to insight NGS solution for laboratories to deliver actionable results; QIAcube robotic workstations, which provides versatile solutions for automated sample processing; QIAxcel for nucleic acid separation; QIAgility, a benchtop instrument for PCR setup; and ESEQuant instruments that enable optical measurement for point of need molecular testing in physician practices, emergency rooms, remote areas, and other applications. It serves molecular diagnostics, applied testing, pharma, and academia customers. QIAGEN N.V. has a collaboration with Bristol-Myers Squibb to develop gene expression profiles for immuno-oncology therapies. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Receive QGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNYSE:QGEN
CUSIPN/A
Phone31-77-355-6600

Debt

Debt-to-Equity Ratio0.52
Current Ratio2.14
Quick Ratio1.94

Price-To-Earnings

Trailing P/E Ratio28.23
Forward P/E Ratio26.99
P/E Growth2.23

Sales & Book Value

Annual Sales$1.42 billion
Price / Sales5.78
Cash Flow$2.3603 per share
Price / Cash15.21
Book Value$11.31 per share
Price / Book3.17

Profitability

EPS (Most Recent Fiscal Year)$1.27
Net Income$40.39 million
Net Margins3.79%
Return on Equity11.91%
Return on Assets6.13%

Miscellaneous

Employees4,684
Outstanding Shares228,230,000

Qiagen (NYSE:QGEN) Frequently Asked Questions

What is Qiagen's stock symbol?

Qiagen trades on the New York Stock Exchange (NYSE) under the ticker symbol "QGEN."

What price target have analysts set for QGEN?

6 equities research analysts have issued 12 month price objectives for Qiagen's stock. Their forecasts range from $37.00 to $40.00. On average, they anticipate Qiagen's share price to reach $38.50 in the next twelve months. View Analyst Ratings for Qiagen.

Who are some of Qiagen's key competitors?

Who are Qiagen's key executives?

Qiagen's management team includes the folowing people:
  • Mr. Peer Michael Schatz, CEO, MD & Member of Management Board (Age 53)
  • Dr. Roland Sackers, CFO, MD & Member of Management Board (Age 50)
  • Mr. Mark Gladwell, Sr. VP of Global Operations (Age 43)
  • Mr. John Gilardi, VP of Corp. Communications & Investor Relations
  • Mr. Jean-Pascal Viola, Head of Corp. Bus. Devel. & Intellectual Property & Litigation and Sr. VP

Has Qiagen been receiving favorable news coverage?

Headlines about QGEN stock have been trending positive on Wednesday, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Qiagen earned a coverage optimism score of 0.40 on Accern's scale. They also assigned media coverage about the company an impact score of 47.09 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

How do I buy shares of Qiagen?

Shares of QGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Qiagen's stock price today?

One share of QGEN stock can currently be purchased for approximately $35.90.

How big of a company is Qiagen?

Qiagen has a market capitalization of $8.16 billion and generates $1.42 billion in revenue each year. The company earns $40.39 million in net income (profit) each year or $1.27 on an earnings per share basis. Qiagen employs 4,684 workers across the globe.

How can I contact Qiagen?

Qiagen's mailing address is HULSTERWEG 82, VENLO P7, 5912 PL. The company can be reached via phone at 31-77-355-6600 or via email at [email protected]


MarketBeat Community Rating for Qiagen (QGEN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  18 (Vote Outperform)
Underperform Votes:  13 (Vote Underperform)
Total Votes:  31
MarketBeat's community ratings are surveys of what our community members think about Qiagen and other stocks. Vote "Outperform" if you believe QGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Qiagen (NYSE:QGEN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Qiagen in the last 12 months. Their average twelve-month price target is $38.50, suggesting that the stock has a possible upside of 7.24%. The high price target for QGEN is $40.00 and the low price target for QGEN is $37.00. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AN/A
Consensus Rating Score: 2.672.50N/AN/A
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $38.50$37.00N/AN/A
Price Target Upside: 7.24% upside15.73% upsideN/AN/A

Qiagen (NYSE:QGEN) Consensus Price Target History

Price Target History for Qiagen (NYSE:QGEN)

Qiagen (NYSE:QGEN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Goldman Sachs GroupReiterated RatingBuyLowView Rating Details
5/3/2018JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
5/3/2018CommerzbankReiterated RatingBuyLowView Rating Details
4/24/2018Deutsche BankReiterated RatingBuy ➝ Buy$38.00 ➝ $40.00LowView Rating Details
4/11/2018Morgan StanleyLower Price TargetOverweight ➝ Overweight$39.00 ➝ $37.00MediumView Rating Details
4/5/2018DZ BankReiterated RatingNeutralMediumView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Qiagen (NYSE:QGEN) Earnings History and Estimates Chart

Earnings by Quarter for Qiagen (NYSE:QGEN)

Qiagen (NYSE:QGEN) Earnings Estimates

Current Year EPS Consensus Estimate: $1.33 EPS
Next Year EPS Consensus Estimate: $1.52 EPS

Qiagen (NYSE QGEN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018Q4 2017$0.42$0.43$394.48 million$396.86 millionViewN/AView Earnings Details
11/6/2017Q3 2017$0.32$0.32$365.10 million$363.98 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.29$0.30$347.27 million$349.00 millionViewN/AView Earnings Details
5/2/2017Q1 2017$0.21$0.22$307.14 million$307.71 millionViewN/AView Earnings Details
2/1/2017Q4 2016$0.39$0.39$371.89 million$366.50 millionViewN/AView Earnings Details
11/2/2016Q3 2016$0.28$0.30$337.79 million$338.70 millionViewN/AView Earnings Details
7/28/2016Q2 2016$0.24$0.25$327.85 million$334.40 millionViewN/AView Earnings Details
4/27/2016Q1 2016$0.20$0.20$294.89 million$298.38 millionViewN/AView Earnings Details
1/2/2016Q4 2015$0.32$0.32$350.40 million$348.54 millionViewN/AView Earnings Details
10/28/2015Q3 2015$0.29$0.28$324.35 million$314.60 millionViewN/AView Earnings Details
7/29/2015Q2 2015$0.26$0.27$317.22 million$319.46 millionViewN/AView Earnings Details
5/5/2015Q1 2015$0.23$0.23$304.31 million$298.43 millionViewN/AView Earnings Details
1/28/2015Q4 2014$0.31$0.26$367.32 million$360.41 millionViewN/AView Earnings Details
10/29/2014Q3 2014$0.28$0.28$336.86 million$336.46 millionViewN/AView Earnings Details
7/29/2014Q2 2014$0.26$0.26$330.28 million$330.84 millionViewN/AView Earnings Details
5/6/2014Q1 2014$0.23$0.23$318.64 million$317.07 millionViewN/AView Earnings Details
1/29/2014Q4 2013$0.34$0.34$363.75 million$361.09 millionViewN/AView Earnings Details
10/29/2013Q3 2013$0.26$0.27$320.10 million$322.11 millionViewN/AView Earnings Details
7/30/2013Q2 2013$0.24$0.25$312.04 million$315.21 millionViewN/AView Earnings Details
4/29/2013Q1 2013$0.23$0.21$306.10 million$303.58 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Qiagen (NYSE:QGEN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Qiagen (NYSE QGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.00%
Institutional Ownership Percentage: 61.80%
Insider Trading History for Qiagen (NYSE:QGEN)

Qiagen (NYSE QGEN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Qiagen (NYSE QGEN) News Headlines

Source:
DateHeadline
$377.91 Million in Sales Expected for Qiagen (QGEN) This Quarter$377.91 Million in Sales Expected for Qiagen (QGEN) This Quarter
www.americanbankingnews.com - May 23 at 1:48 AM
QIAGEN Welcomes WHO’s Essential Diagnostics List Which Includes QuantiFERON-TB GoldQIAGEN Welcomes WHO’s Essential Diagnostics List Which Includes QuantiFERON-TB Gold
finance.yahoo.com - May 22 at 3:15 PM
$0.32 EPS Expected for Qiagen (QGEN) This Quarter$0.32 EPS Expected for Qiagen (QGEN) This Quarter
www.americanbankingnews.com - May 21 at 11:14 PM
Qiagen (QGEN) & The Competition Head to Head SurveyQiagen (QGEN) & The Competition Head to Head Survey
www.americanbankingnews.com - May 20 at 1:19 AM
Qiagen (QGEN) & Its Peers Head to Head SurveyQiagen (QGEN) & Its Peers Head to Head Survey
www.americanbankingnews.com - May 19 at 5:17 PM
Qiagen (QGEN) Given "Buy" Rating at Goldman SachsQiagen (QGEN) Given "Buy" Rating at Goldman Sachs
www.americanbankingnews.com - May 17 at 4:19 PM
QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share RepurchaseQIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase
finance.yahoo.com - May 15 at 5:36 AM
Qiagen (QGEN) & The Competition Critical ComparisonQiagen (QGEN) & The Competition Critical Comparison
www.americanbankingnews.com - May 9 at 11:20 PM
Comparing Qiagen (QGEN) & Its CompetitorsComparing Qiagen (QGEN) & Its Competitors
www.americanbankingnews.com - May 8 at 12:48 PM
Contrasting Qiagen (QGEN) & Its CompetitorsContrasting Qiagen (QGEN) & Its Competitors
www.americanbankingnews.com - May 8 at 3:02 AM
Qiagen Starts Slowly but Is On TrackQiagen Starts Slowly but Is On Track
www.fool.com - May 7 at 6:28 PM
Comparing Seattle Genetics (SGEN) & Qiagen (QGEN)Comparing Seattle Genetics (SGEN) & Qiagen (QGEN)
www.americanbankingnews.com - May 7 at 3:34 AM
Qiagen (QGEN) Receives "Buy" Rating from CommerzbankQiagen (QGEN) Receives "Buy" Rating from Commerzbank
www.americanbankingnews.com - May 4 at 6:01 PM
Qiagens (QGEN) Neutral Rating Reaffirmed at JPMorgan ChaseQiagen's (QGEN) Neutral Rating Reaffirmed at JPMorgan Chase
www.americanbankingnews.com - May 4 at 6:00 PM
Qiagen (QGEN) Expected to Post Earnings of $0.32 Per ShareQiagen (QGEN) Expected to Post Earnings of $0.32 Per Share
www.americanbankingnews.com - May 4 at 4:02 PM
Qiagen (QGEN) Given Consensus Recommendation of "Buy" by BrokeragesQiagen (QGEN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 4 at 12:15 PM
Qiagen (QGEN) Upgraded to Buy by ValuEngineQiagen (QGEN) Upgraded to Buy by ValuEngine
www.americanbankingnews.com - May 3 at 11:10 PM
Deutsche Bank Reaffirms "Buy" Rating for Qiagen (QGEN)Deutsche Bank Reaffirms "Buy" Rating for Qiagen (QGEN)
www.americanbankingnews.com - April 25 at 9:58 AM
Qiagen (QGEN) Price Target Lowered to $37.00 at Morgan StanleyQiagen (QGEN) Price Target Lowered to $37.00 at Morgan Stanley
www.americanbankingnews.com - April 12 at 10:45 AM
Qiagens (QGEN) "Neutral" Rating Reaffirmed at DZ BankQiagen's (QGEN) "Neutral" Rating Reaffirmed at DZ Bank
www.americanbankingnews.com - April 6 at 11:06 AM

SEC Filings

Qiagen (NYSE:QGEN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Qiagen (NYSE QGEN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.